The 2nd International Conference on Drug Discovery & Therapy: Dubai, February 1 - 4, 2010


Session Speaker

The New Approach to Affect the Bioavailibility of Solid Drugs
Valeriy Komarov
Russia

The bioavailability and farmacokinetics of solid-state particles for drug applications prepared from metastable solid-phases is discussed in the context of drug delivery systems. Metastable solid-phases are prepared by drug or joint drug and exipients vapor deposition on solid surface. Stability at storage of final powders was more than 1-2 years.
Since most drugs are solids, drug design must consider solid state properties such as supramolecular structure, the degree and type of dispersivity, and drug and excipient combination efficiency. Modification of these properties may influence the physico-chemical properties and, as a consequence, bioavailability of the drug.
Main advantages of this approach rather to the most common approaches for drug modification, first off all, high universality of technology and ability to solve the problems inaccessible to other approaches, are discussed. For poorly soluble drugs micronization without exipients at certain conditions increased Cmax and decreased Tmax in 2-3 times and at joint micronization usual exipients got ability to considerably change the bioavailability of drugs. The bioavailability of water soluble drugs could be increased in several times or at other conditions of micronization rate and level of drug absorbsion could be strongly reduced, that is necessary for creation of medicinal forms of the prolonged action.

Examples involving different drugs are presented, which led to the formation new polymorphs, new size distribution, new kind of joint solid state with exipients that sharply change physico-chemical behaviour and farmacokinetic properties and could be used to create new drug formulations with enhanced bioavailability or prolonged action.

References:
1. Sergeev, G. B., Komarov, V. S., Mol. Cryst. Liq. Cryst., Vol. 456, pp. 107-115, 2006.
2. Komarov,V. S. (2008). WO 2008/010741 A1.
3. Komarov,V. S. (2008). WO 2008/030134 A1.
4. Komarov, V. S., Morozov, Y.N, Zuev, A.P. (2008). Patent RU23 31409.
5. Komarov, V. S. (2009). Patent RU2347565.



















[Webmaster]   Copyright © 2010 2nd International Conference on Drug Design & Therapy